Kancera AB (publ) (KAN.ST)
SEK 1.22
(9.09%)
SEK 1.22
(9.09%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2023 | -65.04 Million SEK | -27.23% |
| 2022 | -51.93 Million SEK | -14.76% |
| 2021 | -45.25 Million SEK | 2.71% |
| 2020 | -46.51 Million SEK | -30.46% |
| 2019 | -35.65 Million SEK | 22.36% |
| 2018 | -45.92 Million SEK | 18.21% |
| 2017 | -56.14 Million SEK | -151.97% |
| 2016 | -22.28 Million SEK | -13.19% |
| 2015 | -19.68 Million SEK | -22.31% |
| 2014 | -16.09 Million SEK | -54.7% |
| 2013 | -10.4 Million SEK | 68.75% |
| 2012 | -33.29 Million SEK | -81.22% |
| 2011 | -18.37 Million SEK | -156.31% |
| 2010 | -7.16 Million SEK | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 Q2 | -11.35 Million SEK | 15.24% |
| 2024 Q1 | -13.39 Million SEK | 31.06% |
| 2023 Q3 | -10.54 Million SEK | 42.44% |
| 2023 Q4 | -19.42 Million SEK | -84.23% |
| 2023 FY | -66.07 Million SEK | -27.23% |
| 2023 Q2 | -18.32 Million SEK | -6.61% |
| 2023 Q1 | -17.18 Million SEK | -23.0% |
| 2022 Q4 | -13.97 Million SEK | -30.28% |
| 2022 Q3 | -10.72 Million SEK | 30.2% |
| 2022 Q1 | -11.37 Million SEK | 10.68% |
| 2022 Q2 | -15.36 Million SEK | -35.12% |
| 2022 FY | -51.93 Million SEK | -14.76% |
| 2021 Q4 | -12.73 Million SEK | -16.87% |
| 2021 FY | -45.25 Million SEK | 2.71% |
| 2021 Q1 | -9 Million SEK | 30.09% |
| 2021 Q2 | -18.24 Million SEK | -102.62% |
| 2021 Q3 | -10.89 Million SEK | 40.28% |
| 2020 Q2 | -13.88 Million SEK | -24.78% |
| 2020 FY | -46.51 Million SEK | -30.46% |
| 2020 Q3 | -9.32 Million SEK | 32.88% |
| 2020 Q4 | -12.87 Million SEK | -38.14% |
| 2020 Q1 | -11.13 Million SEK | -47.26% |
| 2019 Q1 | -7.9 Million SEK | 36.31% |
| 2019 FY | -35.65 Million SEK | 22.36% |
| 2019 Q4 | -7.55 Million SEK | -1.1% |
| 2019 Q3 | -7.47 Million SEK | 41.22% |
| 2019 Q2 | -12.71 Million SEK | -60.97% |
| 2018 Q4 | -12.4 Million SEK | -16.79% |
| 2018 FY | -45.92 Million SEK | 18.21% |
| 2018 Q3 | -10.62 Million SEK | -4.64% |
| 2018 Q2 | -10.15 Million SEK | 18.7% |
| 2018 Q1 | -12.48 Million SEK | -4.79% |
| 2017 FY | -56.14 Million SEK | -151.97% |
| 2017 Q2 | -17.96 Million SEK | -85.42% |
| 2017 Q1 | -9.69 Million SEK | -49.16% |
| 2017 Q3 | -16.56 Million SEK | 7.8% |
| 2017 Q4 | -11.91 Million SEK | 28.08% |
| 2016 Q3 | -5.24 Million SEK | 4.34% |
| 2016 Q1 | -5.05 Million SEK | 14.16% |
| 2016 FY | -22.28 Million SEK | -13.19% |
| 2016 Q4 | -6.49 Million SEK | -23.85% |
| 2016 Q2 | -5.48 Million SEK | -8.49% |
| 2015 Q4 | -5.88 Million SEK | -71.14% |
| 2015 FY | -19.68 Million SEK | -22.31% |
| 2015 Q1 | -4.93 Million SEK | 2.8% |
| 2015 Q3 | -3.44 Million SEK | 36.5% |
| 2015 Q2 | -5.41 Million SEK | -9.76% |
| 2014 Q2 | -3.8 Million SEK | 8.34% |
| 2014 Q4 | -5.07 Million SEK | -65.76% |
| 2014 FY | -16.09 Million SEK | -54.7% |
| 2014 Q3 | -3.06 Million SEK | 19.43% |
| 2014 Q1 | -4.14 Million SEK | -99.18% |
| 2013 Q4 | -2.08 Million SEK | 23.87% |
| 2013 Q3 | -2.73 Million SEK | 16.43% |
| 2013 Q2 | -3.27 Million SEK | -41.67% |
| 2013 FY | -10.4 Million SEK | 68.75% |
| 2013 Q1 | -2.31 Million SEK | 78.07% |
| 2012 Q3 | -6.34 Million SEK | 26.24% |
| 2012 Q1 | -7.81 Million SEK | -50.38% |
| 2012 Q4 | -10.53 Million SEK | -66.12% |
| 2012 FY | -33.29 Million SEK | -81.22% |
| 2012 Q2 | -8.59 Million SEK | -10.05% |
| 2011 Q1 | 868 Thousand SEK | 115.42% |
| 2011 Q2 | -8.76 Million SEK | -1110.14% |
| 2011 Q3 | -5.27 Million SEK | 39.83% |
| 2011 Q4 | -5.19 Million SEK | 1.52% |
| 2011 FY | -18.37 Million SEK | -156.31% |
| 2010 Q4 | -5.62 Million SEK | -578.89% |
| 2010 FY | -7.16 Million SEK | 0.0% |
| 2010 Q3 | -829 Thousand SEK | -16.6% |
| 2010 Q2 | -711 Thousand SEK | 0.0% |
| Name | Operating Income | Operating Income Difference |
|---|---|---|
| Alligator Bioscience AB (publ) | -248.98 Million SEK | 73.877% |
| Ziccum AB (publ) | -21.56 Million SEK | -201.679% |
| Modus Therapeutics Holding AB (publ) | -16.4 Million SEK | -296.573% |
| BioArctic AB (publ) | 252.64 Million SEK | 125.745% |
| Sprint Bioscience AB (publ) | -845 Thousand SEK | -7597.278% |
| Mendus AB (publ) | -100.65 Million SEK | 35.378% |
| Genovis AB (publ.) | 54.22 Million SEK | 219.951% |
| Intervacc AB (publ) | -93.57 Million SEK | 30.495% |
| QuiaPEG Pharmaceuticals Holding AB (publ) | -15.51 Million SEK | -319.301% |
| Active Biotech AB (publ) | -46.48 Million SEK | -39.923% |
| Magle Chemoswed Holding AB (publ) | 18 Million SEK | 461.164% |
| Bio-Works Technologies AB (publ) | -55.41 Million SEK | -17.368% |
| Aptahem AB (publ) | -10.1 Million SEK | -543.677% |
| Vicore Pharma Holding AB (publ) | -321.5 Million SEK | 79.77% |
| Infant Bacterial Therapeutics AB (publ) | -134.61 Million SEK | 51.684% |
| Fluicell AB (publ) | -26.87 Million SEK | -141.981% |
| Saniona AB (publ) | -81.06 Million SEK | 19.766% |
| Lipigon Pharmaceuticals AB (publ) | -12.37 Million SEK | -425.762% |
| Biovica International AB (publ) | -126.07 Million SEK | 48.409% |
| Spago Nanomedical AB (publ) | -42.5 Million SEK | -53.022% |
| AcouSort AB (publ) | -17.48 Million SEK | -271.945% |
| Xintela AB (publ) | -57.23 Million SEK | -13.634% |
| Abliva AB (publ) | -96.54 Million SEK | 32.632% |
| Egetis Therapeutics AB (publ) | -324.8 Million SEK | 79.975% |
| Karolinska Development AB (publ) | -3.5 Million SEK | -1755.692% |
| OncoZenge AB (publ) | -15.9 Million SEK | -309.018% |
| Amniotics AB (publ) | -29.07 Million SEK | -123.72% |
| 2cureX AB (publ) | -36.36 Million SEK | -78.869% |
| CombiGene AB (publ) | -36.3 Million SEK | -79.154% |
| Asarina Pharma AB (publ) | -14.64 Million SEK | -344.276% |
| Calliditas Therapeutics AB (publ) | -384.39 Million SEK | 83.079% |
| Camurus AB (publ) | 532.35 Million SEK | 112.218% |
| Corline Biomedical AB | -1.78 Million SEK | -3537.696% |
| IRLAB Therapeutics AB (publ) | -180.76 Million SEK | 64.018% |
| Isofol Medical AB (publ) | -41.68 Million SEK | -56.04% |
| I-Tech AB | 24.43 Million SEK | 366.184% |
| Hansa Biopharma AB (publ) | -788.49 Million SEK | 91.751% |
| Cyxone AB (publ) | -21.66 Million SEK | -200.272% |
| ExpreS2ion Biotech Holding AB (publ) | -105.96 Million SEK | 38.619% |
| Biosergen AB | -27.26 Million SEK | -138.555% |
| Cantargia AB (publ) | -290.01 Million SEK | 77.573% |
| NextCell Pharma AB | -43.17 Million SEK | -50.657% |
| Xspray Pharma AB (publ) | -180.76 Million SEK | 64.018% |
| Elicera Therapeutics AB (publ) | -17.09 Million SEK | -280.445% |
| Nanologica AB (publ) | -69.96 Million SEK | 7.034% |
| SynAct Pharma AB | -224.49 Million SEK | 71.028% |
| Annexin Pharmaceuticals AB (publ) | -44.17 Million SEK | -47.234% |
| Stayble Therapeutics AB (publ) | -23.95 Million SEK | -171.526% |
| LIDDS AB (publ) | -40.67 Million SEK | -59.911% |
| Lipum AB (publ) | -37.25 Million SEK | -74.591% |
| BioInvent International AB (publ) | -369.94 Million SEK | 82.418% |
| Alzinova AB (publ) | -16.52 Million SEK | -293.669% |
| Oncopeptides AB (publ) | -253.44 Million SEK | 74.337% |
| Pila Pharma AB (publ) | -6.39 Million SEK | -917.354% |
| Guard Therapeutics International AB (publ) | -115.07 Million SEK | 43.478% |
| Scandinavian ChemoTech AB (publ) | -20.13 Million SEK | -222.965% |
| Simris Alg AB (publ) | -36.63 Million SEK | -77.541% |
| Diamyd Medical AB (publ) | -146.56 Million SEK | 55.623% |
| Xbrane Biopharma AB (publ) | -310.42 Million SEK | 79.048% |
| Ascelia Pharma AB (publ) | -110.91 Million SEK | 41.358% |
| Diagonal Bio AB (publ) | -11.56 Million SEK | -462.355% |